礼来携手勃林格殷格翰研发乳腺癌组合疗法

2016-07-20 佚名不详

制药巨头礼来和勃林格殷格翰近日达成一项研究合作，二者将共同研发乳腺癌联合用药。此次合作的焦点是研究勃林格殷格翰胰岛素样生长因子-1/2（IGF-1/2)配体的中和抗体BI 836845和礼来CDK4/CDK6抑制剂abemaciclib联合疗法在乳腺癌中的安全性和有效性。 Ib期安全性试验将于今年开展，受试者为确诊HR+/HER2-的晚期乳腺癌患者。如果进展顺利，双方继续开展中期临床试验，以及在

制药巨头礼来和勃林格殷格翰近日达成一项研究合作，二者将共同研发乳腺癌联合用药。此次合作的焦点是研究勃林格殷格翰胰岛素样生长因子-1/2（IGF-1/2)配体的中和抗体BI 836845和礼来CDK4/CDK6抑制剂abemaciclib联合疗法在乳腺癌中的安全性和有效性。

Ib期安全性试验将于今年开展，受试者为确诊HR+/HER2-的晚期乳腺癌患者。如果进展顺利，双方继续开展中期临床试验，以及在其它实体瘤中进行临床试验。

勃林格殷格翰实体瘤治疗部门负责人Mehdi Shahidi博士表示，非常高兴能够和礼来展开这次合作，希望联合用药能对转移性乳腺癌患者产生良好的疗效。勃林格的BI 836845已被证实能够抑制肿瘤生长，并且在和诺华Afinitor (everolimus)、辉瑞Aromasin (exemestane)联用的早期临床试验中，已经表现出安全性和有效性。而礼来的abemaciclib作为CDK4和CDK6抑制剂，能够有效抑制肿瘤增殖。勃林格和礼来认为，将这两种药物联用，能够对细胞增殖的信号通路产生更加全面的干扰，进而延长细胞周期阻滞的周期，达到更好的治疗效果。并且这两种药物联用还有可能逆转激素治疗抵抗的现象。

勃林格的肿瘤部门在2013年收获了第一个批文，其肺癌药物Gilotrif (afatinib)获得了FDA的批准。目前勃林格正在努力发展其肿瘤业务。相比而言礼来的肿瘤管线发展更为成熟，其畅销药物Alimta (pemetrexed)、Erbitux (cetuximab)和Gemzar (gemcitabine)都是肿瘤管线的重磅产品。遗憾的是，礼来没有及时赶上免疫治疗这一浪潮，尽管公司和默沙东达成合作协议，但在PD-1/PD-L1抑制剂方面没有拿得出手的候选药物。礼来的abemaciclib已经在乳腺癌中获得了FDA授予的“突破性疗法”认定，有望在不久的将来获批。并且该药物也在许多实体瘤中展开临床试验。

原始出处：

Lilly and Boehringer team up for experimental breast cancer trial pact

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (5)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=240498, encodeId=63ca24049891, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Sep 04 22:17:34 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773054, encodeId=f7961e7305445, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Sun Mar 12 19:17:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131070, encodeId=4d801310e0ce, content=好文，从这里学习了好多新知识，新信息。赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Sep 19 22:59:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299939, encodeId=0fb81299939e3, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Jul 22 03:17:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447224, encodeId=e67b144e22456, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Fri Jul 22 03:17:00 CST 2016, time=2016-07-22, status=1, ipAttribution=)]
2017-09-04 1e145228m78(暂无匿称)

学习了谢谢作者分享!

89 0
[GetPortalCommentsPageByObjectIdResponse(id=240498, encodeId=63ca24049891, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Sep 04 22:17:34 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773054, encodeId=f7961e7305445, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Sun Mar 12 19:17:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131070, encodeId=4d801310e0ce, content=好文，从这里学习了好多新知识，新信息。赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Sep 19 22:59:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299939, encodeId=0fb81299939e3, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Jul 22 03:17:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447224, encodeId=e67b144e22456, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Fri Jul 22 03:17:00 CST 2016, time=2016-07-22, status=1, ipAttribution=)]
2017-03-12 yankaienglish

#组合疗法#

130 0
[GetPortalCommentsPageByObjectIdResponse(id=240498, encodeId=63ca24049891, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Sep 04 22:17:34 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773054, encodeId=f7961e7305445, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Sun Mar 12 19:17:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131070, encodeId=4d801310e0ce, content=好文，从这里学习了好多新知识，新信息。赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Sep 19 22:59:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299939, encodeId=0fb81299939e3, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Jul 22 03:17:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447224, encodeId=e67b144e22456, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Fri Jul 22 03:17:00 CST 2016, time=2016-07-22, status=1, ipAttribution=)]
2016-09-19 ylzr123

好文，从这里学习了好多新知识，新信息。赞了！

118 0
[GetPortalCommentsPageByObjectIdResponse(id=240498, encodeId=63ca24049891, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Sep 04 22:17:34 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773054, encodeId=f7961e7305445, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Sun Mar 12 19:17:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131070, encodeId=4d801310e0ce, content=好文，从这里学习了好多新知识，新信息。赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Sep 19 22:59:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299939, encodeId=0fb81299939e3, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Jul 22 03:17:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447224, encodeId=e67b144e22456, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Fri Jul 22 03:17:00 CST 2016, time=2016-07-22, status=1, ipAttribution=)]
2016-07-22 lqvr

#研发#

49 0
[GetPortalCommentsPageByObjectIdResponse(id=240498, encodeId=63ca24049891, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Sep 04 22:17:34 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773054, encodeId=f7961e7305445, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Sun Mar 12 19:17:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131070, encodeId=4d801310e0ce, content=好文，从这里学习了好多新知识，新信息。赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Sep 19 22:59:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299939, encodeId=0fb81299939e3, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Jul 22 03:17:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447224, encodeId=e67b144e22456, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Fri Jul 22 03:17:00 CST 2016, time=2016-07-22, status=1, ipAttribution=)]
2016-07-22 ymljack

#勃林格殷格翰#

56 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

药械

礼来携手勃林格殷格翰研发乳腺癌组合疗法

相关资讯

科室

工具

服务